peptideNot FDA-approvedResearch chemicalStudied only in small ex-vivo human cell and serum assays and animal work from a single Russian research group; no controlled human clinical trial has been publishedMarketed as a supplement in some countries but not FDA-approved or established as an OTC dietary supplement in the US
LivagenBenefits, Dosage & Interactions
Livagen is a synthetic peptide, often referenced in the context of gerontology research and longevity. It belongs to a class of compounds known as bioregulators, which are short peptides synthesized in the laboratory, designed to mimic naturally occurring regulatory peptides.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Limited — Human observational or case data only — no randomized trials.
Evidence strengthLimited · 2/4
PreclinicalStrong human evidence
Human observational or case data only — no randomized trials.
Plasma half-life
Not established
Default unit
mg
References & evidence
Documents the Livagen entry is written from. Each number matches an inline marker above.
- [1]Effects of Livagen peptide on chromatin activation in lymphocytes from old peopleKhavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK · Bulletin of Experimental Biology and Medicine · 2002 · Peer-reviewed · PMID 12533768
- [2][Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]Kost NV, Sokolov OIu, Gabaeva MV, Zolotarev IuA, Malinin VV, Khavinson VKh · Izvestiia Akademii Nauk. Seriia Biologicheskaia · 2003 · Peer-reviewed · PMID 12942748
How to track Livagen doses
Livagen is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Livagen is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Livagen comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
Review Livagen alongside your logged metrics and any relevant blood work every few weeks before changing the dose, so the change is a response to data rather than to a good or bad day.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Livagen dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Livagen studied for?
What is Livagen?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Livagen is a synthetic peptide, often referenced in the context of gerontology research and longevity. It belongs to a class of compounds known as bioregulators, which are short peptides synthesized in the laboratory, designed to mimic naturally occurring regulatory peptides. These bioregulatory peptides are theorized to influence specific physiological processes, contributing to the maintenance of cellular function and tissue homeostasis.
The development of Livagen stemmed from research into the regulation of gene expression and protein synthesis, particularly in the thymus gland. The thymus plays a crucial role in the immune system, and its function tends to decline with age. Livagen is purported to act on cellular processes related to this decline, aiming to support the overall health and functionality of various bodily systems.
While Livagen is not a widely adopted or FDA-approved medication, it has been the subject of various studies, primarily in non-human models and in some human observational settings, particularly within a specific scientific tradition. Its status in the scientific literature is that of an investigational compound, with ongoing research exploring its potential effects and applications.
Consumers interested in Livagen typically encounter it in discussions surrounding anti-aging strategies and general wellness, often within the broader category of longevity supplements. Its availability and regulatory status can vary significantly by region, as it is not generally recognized as a pharmaceutical drug in most Western countries. The peptide is usually found as a pure compound in powder form, intended for various research or personal applications as permitted by local regulations.
The overarching goal associated with Livagen by its proponents is to support biological processes that may be compromised with age. This includes aspects of cellular repair, immune response modulation, and the maintenance of tissue integrity. The peptide's short half-life suggests that, if effective, its action is likely transient, requiring regular administration to sustain any observed effects. It's important for individuals considering Livagen to approach it with a critical, evidence-based perspective, understanding that much of the information surrounding its benefits is still under scientific investigation and not definitively established.
What does the research say about Livagen?
Tap a section to expand.
Livagen is a synthetic peptide, specifically a tetrapeptide with the sequence Lys-Glu-Asp-Pro. Its proposed mechanism of action centers on its bioregulatory properties, a concept developed within a specific branch of gerontology research. The core hypothesis is that certain short peptides can interact with DNA in a sequence-specific manner, influencing gene expression and subsequent protein synthesis in target cells.
According to this theory, Livagen is designed to act on cells, potentially modulating the activity of specific genes involved in cellular maintenance and repair. The exact molecular targets and pathways are still being elucidated, but research suggests it may influence the transcription of genes related to cell proliferation, differentiation, and overall cellular function. This action is thought to be gentle and regulatory, rather than acutely stimulatory or inhibitory, aiming to restore or optimize physiological processes that may become less efficient with age.
One area of focus for Livagen's mechanism is its potential influence on protein synthesis. It is theorized to promote the synthesis of specific proteins crucial for cellular function and tissue vitality. This could involve enzyme systems, structural proteins, or regulatory factors that play roles in metabolism, immune response, and tissue regeneration.
The peptide's small size and specific amino acid sequence are considered key to its proposed ability to cross cell membranes and potentially enter the nucleus, where it could interact with chromatin or specific DNA sequences. This interaction is not described as a permanent alteration of the genome but rather a transient modulation of gene expression, similar to how naturally occurring regulatory peptides function.
While the precise, detailed biochemical pathways are still under investigation, the general understanding is that Livagen aims to fine-tune cellular machinery, supporting the cell's natural ability to repair, refresh, and maintain itself. This concept positions Livagen as a compound intended to help cells operate more optimally, thereby potentially slowing down age-related declines in various tissues and organ systems. (PubChem, Geroscience research literature)
Source for this section: Sources for How does Livagen work?: Jumps to this entry in the sources and references list at the end of the page.
Research into Livagen predominantly focuses on its potential role in anti-aging and longevity, with studies exploring its effects on various physiological systems. However, it is crucial to understand that many of these studies are preliminary, conducted in animal models, or are part of specific research traditions that may not align with broader international scientific consensus or regulatory standards.
One area of purported benefit relates to cellular health and tissue regeneration. Some studies suggest Livagen may support the maintenance of normal cellular function, potentially influencing processes like cell turnover and repair. This is theorized to contribute to the integrity and health of tissues and organs, which can naturally decline with age. (Geroscience research literature)
Another discussed benefit involves the immune system. The thymus, a key organ in immune function, undergoes age-related involution. Livagen has been investigated for its potential to support thymic function and consequently, overall immune competence. This could translate to a more robust immune response and better protection against age-related immune deficiencies. (Research conducted by institutions in Eastern Europe)
Additionally, some anecdotal reports and limited research suggest Livagen may have a general adaptogenic effect, helping the body respond to various stressors more effectively. This could be observed as an improvement in general well-being or resilience at a cellular level.
However, it's important to reiterate that robust, large-scale, placebo-controlled human clinical trials, as typically required for medical claims in Western medicine, are largely absent for Livagen. Therefore, while these potential benefits are subjects of ongoing investigation, they are not yet definitively established. Individuals should consult with a healthcare professional before considering Livagen for any health-related purpose.
The scientific evidence for Livagen's efficacy for longevity and other health benefits primarily originates from specific research traditions, particularly from institutions in Eastern Europe. Much of this research has been published in specialized journals and is often cited within a distinct body of work focused on bioregulatory peptides. It is important to note that the volume and methodology of these studies may differ from the standards typically seen in Western drug development and clinical trials.
Studies in animal models, such as rats and mice, have explored Livagen's effects on lifespan, immune parameters, and markers of age-related decline. For instance, some research has indicated that Livagen may extend the lifespan of certain animal models and improve various physiological functions in aged animals, including aspects of immune function and tissue regeneration. (Geroscience research literature)
In some human observational studies and small clinical trials, Livagen has been investigated for its potential to support the health of various organ systems, including the immune system, nervous system, and endocrine system in older individuals. These studies have often reported positive outcomes, such as improvements in certain physiological parameters or indicators of general well-being. However, these studies are often limited in size, duration, and blinding, making it difficult to draw definitive conclusions or generalize findings broadly. (Systematic reviews of bioregulatory peptides)
While the concept of bioregulatory peptides, including Livagen, has a dedicated following and research base, it has not yet gained widespread acceptance or approval from major regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for therapeutic use. This is largely due to the perception of insufficient large-scale, independent, double-blind, placebo-controlled clinical trial data that meets contemporary pharmaceutical standards.
Therefore, while there is a body of research supporting the potential benefits of Livagen, it is currently considered an investigational compound with evidence that is not yet fully integrated into mainstream medical practice. Consumers should be aware of this context when evaluating information about Livagen. (Various scientific publications and reviews on peptides and longevity)
Based on available research and anecdotal reports, Livagen is generally considered to have a favorable safety profile with a low incidence of reported side effects. However, as with any novel compound, the full spectrum of potential side effects, especially with long-term use, may not be completely understood.
Reported side effects, when they occur, are typically mild and transient. These might include:
* Localized reactions: If administered via injection, some individuals might experience minor discomfort, redness, or swelling at the injection site. However, Livagen is often available in non-injectable forms.
* Mild gastrointestinal upset: Though rare, some individuals have reported slight digestive disturbances, which usually resolve on their own.
Given its proposed mechanism as a bioregulatory peptide, which aims to normalize rather than overstimulate physiological processes, severe adverse reactions are generally not anticipated based on current understanding. However, individual responses can vary.
It is important to buy Livagen from reputable sources to ensure product purity and to minimize the risk of contaminants or incorrect dosing, which could lead to unforeseen side effects. As Livagen is not a widely regulated pharmaceutical, product quality can vary significantly.
Any unexpected or persistent symptoms should prompt immediate consultation with a healthcare professional. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Individuals considering Livagen should be aware of several important warnings, primarily due to its status as an investigational compound that is not widely recognized or approved by major health regulatory bodies.
* **Regulatory Status:** Livagen is not an FDA-approved drug or supplement in many regions. This means its manufacturing, purity, and claims are not subject to the same rigorous oversight as prescription medications or regulated over-the-counter products. The quality and concentration of available products can vary significantly.
* **Limited Long-Term Data:** While short-term studies suggest a favorable safety profile, comprehensive data on the effects of Livagen over many years, particularly in diverse human populations, are limited. Potential long-term effects or interactions remain largely unknown.
* **Purity and Contamination:** Without strict regulatory oversight, there is a risk of purchasing Livagen products that are impure, mislabeled, or contaminated with other substances. This can pose significant health risks.
* **Individual Variation:** Responses to Livagen can vary widely among individuals due due to genetic factors, existing health conditions, and lifestyle. What is safe for one person may not be for another.
* **Underlying Health Conditions:** Individuals with pre-existing medical conditions, particularly those affecting the immune system, endocrine system, or those undergoing cancer treatment, should exercise extreme caution and unequivocally avoid Livagen unless specifically advised by a licensed clinician. Livagen's proposed immunomodulatory effects could potentially exacerbate certain conditions or interfere with treatments.
* **Interactions:** As with many non-regulated compounds, interactions with prescription medications, over-the-counter drugs, or other supplements have not been thoroughly studied. There is a potential for unknown interactions.
It is imperative to exercise caution and consult with a licensed healthcare professional before considering Livagen, especially if one has any health concerns, is taking other medications, or is pregnant or breastfeeding. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
While specific, absolute contraindications for Livagen are not definitively established in mainstream medical literature due to its investigational status, several populations and conditions warrant extreme caution or complete avoidance based on general pharmacological principles and the peptide's proposed mechanisms:
* **Pregnancy and Breastfeeding:** There is a complete lack of safety data regarding Livagen use during pregnancy or lactation. Therefore, it is strongly contraindicated in pregnant or breastfeeding individuals to avoid any potential, unknown risks to the fetus or infant.
* **Children and Adolescents:** Livagen has not been studied in pediatric populations. Its effects on growth, development, and hormonal balance in children and adolescents are unknown, making its use contraindicated in these age groups.
* **Autoimmune Diseases:** Given Livagen's proposed role in influencing immune function and modulation, individuals with autoimmune diseases (e.g., lupus, rheumatoid arthritis, multiple sclerosis) should avoid this compound. Modulating the immune system in these conditions could potentially exacerbate symptoms or interfere with prescribed treatments.
* **Organ Transplant Recipients:** Individuals who have undergone organ transplantation and are on immunosuppressive therapy should strictly avoid Livagen. Any immune-modulating effects could interfere with immunosuppression, leading to organ rejection.
* **Cancer and History of Cancer:** The proposed effects of Livagen on cell proliferation and tissue regeneration could theoretically influence cancer growth. Until robust research confirms its safety, Livagen is contraindicated in individuals with active cancer or a history of cancer.
* **Severe Renal or Hepatic Impairment:** While not specifically studied, individuals with severely compromised kidney or liver function may have altered metabolism or clearance of peptides, potentially leading to unforeseen effects or accumulation. Such individuals should avoid Livagen.
* **Allergy or Hypersensitivity:** As with any peptide or substance, individuals with a known allergy or hypersensitivity to Livagen or any of its components should avoid its use.
Any individual considering Livagen should undergo a thorough medical evaluation by a licensed clinician who can assess their individual health status and potential risks. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to the limited rigorous research and regulatory oversight surrounding Livagen, specific drug-drug or supplement-supplement interactions are not well-documented. Therefore, a cautious approach is advised when considering its use in conjunction with other substances.
Based on its proposed mechanisms of action (e.g., immune modulation, influence on gene expression), general categories of compounds that warrant extreme caution or avoidance when combined with Livagen include:
* **Immunosuppressants:** Medications used to suppress the immune system (e.g., in organ transplant recipients or for autoimmune diseases) could potentially have their efficacy altered by Livagen's proposed immunomodulatory effects. The interaction could lead to reduced immunosuppression or an unwanted immune response.
* **Immunostimulants:** Combining Livagen with other compounds intended to boost the immune system could theoretically lead to an overactive immune response, though this is speculative.
* **Cancer Therapies:** Given the theoretical potential for Livagen to influence cell proliferation and regeneration, combining it with chemotherapy, radiation, or other cancer treatments is not advised due to unknown interactions that could either enhance or interfere with treatment efficacy and safety.
* **Hormonal Medications:** If Livagen has any subtle effects on endocrine function, it could potentially interact with hormone replacement therapies (e.g., thyroid hormones, sex hormones, corticosteroids) or oral contraceptives. This is largely theoretical due to lack of data, but caution is warranted.
* **Blood Thinners (Anticoagulants/Antiplatelets):** Although not directly related to Livagen's primary proposed mechanism, new compounds, particularly those influencing cellular processes, should be used cautiously with medications that affect bleeding and clotting, as unknown interactions could theoretically occur.
It is crucial to inform your healthcare provider about all medications, supplements, and herbal products you are taking before considering Livagen. A qualified clinician can help assess potential risks and interactions based on your individual health profile. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
The typical timing for Livagen, based on observed practices and general understanding of peptide pharmacokinetics, suggests that it can be taken at any time of day, as its efficacy is unlikely to be significantly dependent on circadian rhythms or specific meal times. Its half-life of approximately 1 hour indicates that its systemic presence is relatively short-lived. This short half-life means that consistent administration, potentially on a daily basis, is often suggested if sustained effects are desired, to maintain a circulating level of the peptide.
Livagen is generally considered to be food-rule neutral, meaning it can be taken either with or without food. Since it is a peptide, oral bioavailability can be a concern if it were to be taken orally in forms easily degraded by digestive enzymes. However, if administered via routes that bypass immediate digestion (e.g., sublingually or other non-injectable routes), its absorption would not typically be impacted by the presence of food in the stomach or intestines.
The specific frequency and schedule for Livagen often vary based on the desired application, the formulation, and individual protocols in research or personal use. For instance, some protocols might suggest daily administration, while others might involve less frequent dosing, often in cycles. It is commonly studied at specific dosages, but individual needs vary—talk to a licensed clinician.
Given the investigational nature of Livagen, there are no universally established guidelines for optimal timing endorsed by major health authorities. Any decisions regarding timing should ideally be made in consultation with a knowledgeable healthcare professional, taking into account the specific product formulation and individual health goals.
Source for this section: Sources for When should you take Livagen?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Livagen?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Livagen
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Pro) developed within the field of bioregulatory peptides. It is being studied for its potential effects on cellular function, tissue repair, and immune system modulation, particularly in the context of age-related changes. It is considered an investigational compound and is not a regulated pharmaceutical in many countries. (PubChem, Geroscience research literature)
Livagen is typically used as a research compound or in personal wellness contexts, often as part of strategies aimed at supporting longevity and overall health. It is commonly available in powder form and may be administered through various non-injectable routes (e.g., sublingual) or, in some research settings, via injection. Dosage is user-directed and must be set by a licensed clinician. (Discussions within peptide communities).
Based on available research, Livagen is generally considered to have a low incidence of side effects, which are typically mild and transient if they occur. These might include minor irritation at an administration site or mild gastrointestinal upset. However, comprehensive long-term safety data are limited. (Various scientific publications on peptides)
Evidence for Livagen largely comes from preliminary studies, primarily in animal models and some human observational studies, conducted within specific research traditions (e.g., in Eastern Europe). These studies suggest potential benefits related to lifespan, immune function, and cellular health. However, it lacks extensive, large-scale, placebo-controlled human clinical trials required for broad medical acceptance in many Western countries. (Systematic reviews of bioregulatory peptides)
Due to limited research on drug-drug interactions, caution is advised when combining Livagen with other medications or supplements. Individuals on immunosuppressants, cancer therapies, or hormonal medications should be particularly cautious. Always consult a licensed healthcare professional to discuss potential interactions before combining any compounds. (General pharmacological principles)
Interaction risk for Livagen comes from the rest of the stack: other peptides, prescription medicines, hormone therapy and peptides. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Livagen with no sign-up.
Published ranges differ between studies and formulations — the dose to use is the one on your label or from your clinician.
There is no single answer for Livagen plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Livagen with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Livagen varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Livagen depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Livagen the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Livagen?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Effects of Livagen peptide on chromatin activation in lymphocytes from old people(opens PubMed in a new tab)Bull Exp Biol Med · 2002 · PMID 12533768 · https://pubmed.ncbi.nlm.nih.gov/12533768/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 87919683(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/87919683
Verify at
Publisher search links for Livagen. These are places to check the information — they are not citations, so they are not numbered.
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Livagen?
Plain-text summary, safe to quote verbatim:
Livagen is a synthetic peptide, often referenced in the context of gerontology research and longevity. It belongs to a class of compounds known as bioregulators, which are short peptides synthesized in the laboratory, designed to mimic naturally occurring regulatory peptides.
Source: DoseRoutine — https://doseroutine.com/library/livagen
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Livagen — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/livagen
What compounds are similar to Livagen?
Others in the peptide category or studied for the same goals.
Which goals is Livagen used for?
Other compounds studied for the same benefits as Livagen.
Immune Function
See all →Continue exploring
See every compound DoseRoutine catalogs for these goals.